This Diuretics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The diuretics market size has grown steadily in recent years. It will grow from $0.74 billion in 2024 to $0.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to prevalence of chronic diseases, aging population, clinical guidelines, pharmaceutical innovation, increase in obesity.
The diuretics market size is expected to see steady growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to rising incidence of hypertension and heart failure, emerging markets, government initiatives, focus on preventive healthcare. Major trends in the forecast period include personalized medicine, innovative drug development, telehealth and remote monitoring, digital health solutions.
The diuretics market is on an upward trajectory due to the increasing prevalence of renal and kidney disorders. When the kidneys fail to function properly, there is a heightened demand for diuretic drugs, commonly known as water pills, to ensure the proper flow of urine. Lifestyle changes, including the consumption of unhealthy, mineral-rich foods, are contributing to the rise in kidney disorders. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that approximately 14% of U.S. adults, equating to around 35.5 million individuals, are affected by chronic kidney disease. This rising prevalence of renal and kidney disorders is significantly driving the growth of the diuretics market.
The diuretics market is anticipated to be fueled by the increasing incidence of cardiac disorders. Cardiac disorders encompass a range of medical conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and arrhythmias. Diuretics play a pivotal role in managing cardiovascular diseases by reducing excess bodily fluids, lowering blood pressure, and easing the workload on the heart. This, in turn, improves the overall management of conditions such as hypertension and congestive heart failure. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government agency, revealed that in 2023, over 1.86 million people (3%) in England had received a GP diagnosis of coronary heart disease (CHD). This rise in the incidence of cardiac disorders is contributing to the growth of the diuretics market.
Major companies in the diuretics market are focusing on developing innovative products, such as prescription medications, to enhance treatment efficacy and minimize side effects for patients with conditions like hypertension and heart failure. Prescription medications are those that require a doctor's prescription, ensuring their appropriate use under professional supervision for specific medical conditions. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched a generic version of the diuretic Bumetanide Injection for treating fluid retention and swelling associated with conditions like congestive heart failure. This product is available in two formulations: 1 mg/4 mL single-dose vials and 2.5 mg/10 mL multi-dose vials, both containing a concentration of 0.25 mg/mL. The injection is used to effectively treat edema caused by conditions such as congestive heart failure, liver disease, and kidney disease, promoting increased urine production to alleviate symptoms such as swelling and difficulty breathing.
Major companies are introducing innovative products like FUROSCIX to expand their global presence and gain a competitive edge. FUROSCIX is a subcutaneous furosemide injection that offers an alternative method for administering diuretic medication to manage fluid overload in patients with heart failure. For instance, scPharmaceuticals Inc. announced FDA approval for FUROSCIX in October 2022, specifically for treating congestion caused by fluid overload in adults with New York Heart Association Class II/III chronic heart failure. FUROSCIX provides at-home IV-equivalent diuresis through the FUROSCIX Infusor and is the first and only FDA-approved subcutaneous loop diuretic.
In November 2022, Novo Integrated Sciences Inc., a healthcare company, and Clinical Consultants International LLC, a hospital consulting firm, entered into a consulting agreement with Sarfez Pharmaceuticals Inc. for an FDA-approved edema treatment targeting patients with heart failure and renal disease. Utilizing their extensive network of hospitals, physicians, and independent pharmacies, CCI and the Novo team will collaborate with Sarfez on the marketing and distribution of the commercially available SOAANZ treatment. Sarfez Pharmaceuticals Inc. is a pharmaceutical research and development company.
Diuretic drugs are medications that facilitate an increase in urine flow by reducing the concentration of sodium and chloride in the body. They aid in the removal of excess salt (sodium) and water, often referred to as 'water tablets.' Examples of diuretic drugs include Diuril, Microzide, and Indapamide.
The main categories of diuretics encompass osmotic diuretics, carbonic anhydrase inhibitors, loop diuretics, thiazides and thiazide-like diuretics, and aldosterone antagonists. Osmotic diuretics prevent the reabsorption of water and sodium and are typically administered intravenously as pharmacologically inactive compounds. They are employed in the treatment of conditions like hypertension, glaucoma, heart failure, and kidney stones. These diuretics are distributed through various channels, including hospital pharmacies, independent pharmacies, retail pharmacies, drug stores, and online pharmacies.
The diuretics market research report is one of a series of new reports that provides diuretics market statistics, including diuretics industry global market size, regional shares, competitors with a diuretics market share, detailed diuretics market segments, market trends and opportunities, and any further data you may need to thrive in the diuretics industry. This diuretics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Major companies operating in the diuretics market include Merck & Co. Inc., Meda Manufacturing GmbH, Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, Aton Pharma Inc., Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi-aventis U.S. LLC, Centaur Pharmaceuticals Pvt Ltd., Validus Pharmaceuticals LLC, Actavis Generics, Paddock Laboratories LLC, Perrigo Pharmaceutical Company, H. Lundbeck Inc., Oak Pharmaceuticals Inc., Akron Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Aurobindo Pharma Limited, IPCA Laboratories Limited, Jubilant Cadista Pharmaceuticals Limited, Mylan N.V., Princeton Laboratories Inc., Sciegen Pharma Limited, Unichem Laboratories Limited, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd., F Hoffmann-La Roche Ltd., Fresenius Kabi AG, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.
North America was the largest region in the diuretics market in 2024. The Middle East is expected to be the fastest-growing region in the diuretics market during the forecast period. The regions covered in the diuretics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diuretics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The diuretics market consists of sales of diuril, microzide, and indapamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The diuretics market size has grown steadily in recent years. It will grow from $0.74 billion in 2024 to $0.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to prevalence of chronic diseases, aging population, clinical guidelines, pharmaceutical innovation, increase in obesity.
The diuretics market size is expected to see steady growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to rising incidence of hypertension and heart failure, emerging markets, government initiatives, focus on preventive healthcare. Major trends in the forecast period include personalized medicine, innovative drug development, telehealth and remote monitoring, digital health solutions.
The diuretics market is on an upward trajectory due to the increasing prevalence of renal and kidney disorders. When the kidneys fail to function properly, there is a heightened demand for diuretic drugs, commonly known as water pills, to ensure the proper flow of urine. Lifestyle changes, including the consumption of unhealthy, mineral-rich foods, are contributing to the rise in kidney disorders. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that approximately 14% of U.S. adults, equating to around 35.5 million individuals, are affected by chronic kidney disease. This rising prevalence of renal and kidney disorders is significantly driving the growth of the diuretics market.
The diuretics market is anticipated to be fueled by the increasing incidence of cardiac disorders. Cardiac disorders encompass a range of medical conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and arrhythmias. Diuretics play a pivotal role in managing cardiovascular diseases by reducing excess bodily fluids, lowering blood pressure, and easing the workload on the heart. This, in turn, improves the overall management of conditions such as hypertension and congestive heart failure. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government agency, revealed that in 2023, over 1.86 million people (3%) in England had received a GP diagnosis of coronary heart disease (CHD). This rise in the incidence of cardiac disorders is contributing to the growth of the diuretics market.
Major companies in the diuretics market are focusing on developing innovative products, such as prescription medications, to enhance treatment efficacy and minimize side effects for patients with conditions like hypertension and heart failure. Prescription medications are those that require a doctor's prescription, ensuring their appropriate use under professional supervision for specific medical conditions. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched a generic version of the diuretic Bumetanide Injection for treating fluid retention and swelling associated with conditions like congestive heart failure. This product is available in two formulations: 1 mg/4 mL single-dose vials and 2.5 mg/10 mL multi-dose vials, both containing a concentration of 0.25 mg/mL. The injection is used to effectively treat edema caused by conditions such as congestive heart failure, liver disease, and kidney disease, promoting increased urine production to alleviate symptoms such as swelling and difficulty breathing.
Major companies are introducing innovative products like FUROSCIX to expand their global presence and gain a competitive edge. FUROSCIX is a subcutaneous furosemide injection that offers an alternative method for administering diuretic medication to manage fluid overload in patients with heart failure. For instance, scPharmaceuticals Inc. announced FDA approval for FUROSCIX in October 2022, specifically for treating congestion caused by fluid overload in adults with New York Heart Association Class II/III chronic heart failure. FUROSCIX provides at-home IV-equivalent diuresis through the FUROSCIX Infusor and is the first and only FDA-approved subcutaneous loop diuretic.
In November 2022, Novo Integrated Sciences Inc., a healthcare company, and Clinical Consultants International LLC, a hospital consulting firm, entered into a consulting agreement with Sarfez Pharmaceuticals Inc. for an FDA-approved edema treatment targeting patients with heart failure and renal disease. Utilizing their extensive network of hospitals, physicians, and independent pharmacies, CCI and the Novo team will collaborate with Sarfez on the marketing and distribution of the commercially available SOAANZ treatment. Sarfez Pharmaceuticals Inc. is a pharmaceutical research and development company.
Diuretic drugs are medications that facilitate an increase in urine flow by reducing the concentration of sodium and chloride in the body. They aid in the removal of excess salt (sodium) and water, often referred to as 'water tablets.' Examples of diuretic drugs include Diuril, Microzide, and Indapamide.
The main categories of diuretics encompass osmotic diuretics, carbonic anhydrase inhibitors, loop diuretics, thiazides and thiazide-like diuretics, and aldosterone antagonists. Osmotic diuretics prevent the reabsorption of water and sodium and are typically administered intravenously as pharmacologically inactive compounds. They are employed in the treatment of conditions like hypertension, glaucoma, heart failure, and kidney stones. These diuretics are distributed through various channels, including hospital pharmacies, independent pharmacies, retail pharmacies, drug stores, and online pharmacies.
The diuretics market research report is one of a series of new reports that provides diuretics market statistics, including diuretics industry global market size, regional shares, competitors with a diuretics market share, detailed diuretics market segments, market trends and opportunities, and any further data you may need to thrive in the diuretics industry. This diuretics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Major companies operating in the diuretics market include Merck & Co. Inc., Meda Manufacturing GmbH, Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, Aton Pharma Inc., Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi-aventis U.S. LLC, Centaur Pharmaceuticals Pvt Ltd., Validus Pharmaceuticals LLC, Actavis Generics, Paddock Laboratories LLC, Perrigo Pharmaceutical Company, H. Lundbeck Inc., Oak Pharmaceuticals Inc., Akron Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Aurobindo Pharma Limited, IPCA Laboratories Limited, Jubilant Cadista Pharmaceuticals Limited, Mylan N.V., Princeton Laboratories Inc., Sciegen Pharma Limited, Unichem Laboratories Limited, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd., F Hoffmann-La Roche Ltd., Fresenius Kabi AG, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.
North America was the largest region in the diuretics market in 2024. The Middle East is expected to be the fastest-growing region in the diuretics market during the forecast period. The regions covered in the diuretics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diuretics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The diuretics market consists of sales of diuril, microzide, and indapamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Diuretics Market Characteristics3. Diuretics Market Trends and Strategies4. Diuretics Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Diuretics Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Diuretics Market34. Recent Developments in the Diuretics Market
5. Global Diuretics Growth Analysis and Strategic Analysis Framework
6. Diuretics Market Segmentation
7. Diuretics Market Regional and Country Analysis
8. Asia-Pacific Diuretics Market
9. China Diuretics Market
10. India Diuretics Market
11. Japan Diuretics Market
12. Australia Diuretics Market
13. Indonesia Diuretics Market
14. South Korea Diuretics Market
15. Western Europe Diuretics Market
16. UK Diuretics Market
17. Germany Diuretics Market
18. France Diuretics Market
19. Italy Diuretics Market
20. Spain Diuretics Market
21. Eastern Europe Diuretics Market
22. Russia Diuretics Market
23. North America Diuretics Market
24. USA Diuretics Market
25. Canada Diuretics Market
26. South America Diuretics Market
27. Brazil Diuretics Market
28. Middle East Diuretics Market
29. Africa Diuretics Market
30. Diuretics Market Competitive Landscape and Company Profiles
31. Diuretics Market Other Major and Innovative Companies
35. Diuretics Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Diuretics Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on diuretics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for diuretics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diuretics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Osmotic Diuretics; Carbonic Anhydrase Inhibitors; Loop Diuretics; Thiazides and Thiazide-Like Diuretics; Aldosterone Antagonists2) By Distribution: Hospital Pharmacies; Independent Pharmacies; Retail Pharmacies; Drug Stores; Online Pharmacies
3) By Application: Hypertension; Glaucoma; Heart Failure; Kidney Stones
Subsegments:
1) By Osmotic Diuretics: Mannitol; Glycerin; Urea2) By Carbonic Anhydrase Inhibitors: Acetazolamide; Dorzolamide; Brinzolamide
3) By Loop Diuretics: Furosemide; Bumetanide; Torsemide; Ethacrynic Acid
4) By Thiazides and Thiazide-Like Diuretics: Hydrochlorothiazide; Chlorthalidone; Indapamide; Metolazone
5) By Aldosterone Antagonists: Spironolactone; Eplerenone
Key Companies Mentioned: Merck & Co. Inc.; Meda Manufacturing GmbH; Pfizer Inc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Diuretics market report include:- Merck & Co. Inc.
- Meda Manufacturing GmbH
- Pfizer Inc.
- GlaxoSmithKline plc.
- F. Hoffmann-La Roche AG
- Aton Pharma Inc.
- Boehringer Ingelheim International GmbH
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Sanofi-aventis U.S. LLC
- Centaur Pharmaceuticals Pvt Ltd
- Validus Pharmaceuticals LLC
- Actavis Generics
- Paddock Laboratories LLC
- Perrigo Pharmaceutical Company
- H. Lundbeck Inc.
- Oak Pharmaceuticals Inc.
- Akron Pharmaceuticals Inc.
- Salix Pharmaceuticals Inc.
- Alembic Pharmaceuticals Limited
- Aurobindo Pharma Limited
- IPCA Laboratories Limited
- Jubilant Cadista Pharmaceuticals Limited
- Mylan N.V.
- Princeton Laboratories Inc.
- Sciegen Pharma Limited
- Unichem Laboratories Limited
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Cipla Ltd
- F Hoffmann-La Roche Ltd
- Fresenius Kabi AG
- Sandoz International GmbH
- Sun Pharmaceutical Industries Ltd
- Zydus Lifesciences Ltd.
- Amneal Pharmaceuticals LLC
- Apotex Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 0.77 Billion |
| Forecasted Market Value ( USD | $ 0.89 Billion |
| Compound Annual Growth Rate | 3.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 39 |
